论文部分内容阅读
目的 检测 Periostin 在人小细胞肺癌(SCLC)细胞株及临床组织标本中的表达差异,探究其对 SCLC 患者化疗耐药性的影响.方法 通过检测 Periostin mRNA 及蛋白在人 SCLC H69 与 H69AR 中的表达差异,借助 Periostin 重组质粒转染上调 H69 细胞中 Periostin 的表达,比较转染后的 H69 细胞在不同浓度的化疗药物 (顺铂,依托泊苷)中的存活率与空载对照组的差异.检测临床 SCLC 化疗敏感和耐药患者病理标本的 Periostin免疫组织化学结果.结果 Periostin 在 H69AR 内的 mRNA 表达水平显著高于 H69(1.49±0.21 vs. 0.81±0.11, P<0.05),Periostin 蛋白在 H69AR 内的表达水平显著高于 H69(3.29±0.41 vs. 1.34±0.20,P<0.05).Periostin 重组质粒转染 H69 细胞后,在相同浓度的化疗药物(顺铂,依托泊苷)中存活率显著提高,处理主效应(P<0.05).临床 SCLC 组织标本中 Periostin 阳性表达率为 67.44％,而且化疗敏感组低于耐药组(13/24 vs. 16/19,χ2=4.359, P=0.037).结论 Periostin 在 SCLC 细胞敏感株 H69 中的表达明显低于耐药株 H69AR,Periostin 在 SCLC 组织中过表达可增强化疗耐药性,还需进一步研究其机制.“,”Objective To detect the difference of periostin expression in small cell lung cancer (SCLC) cell, and explore its effect on chemoresistance of SCLC patients. Methods The expression of periostin in mRNA and protein was detected by RT-PCR and Western blot analysis in SCLC H69 and multidrug resistant strain H69AR. The expression of periostin was up-regulated by recombinant plasmid-periostin in H69 cell. The survival rate in the transfected group was different from that of the negative control group and uninterrupted group. Results The expression of periostin mRNA and protein in the sensitive strain H69 was lower than that of the multidrug resistant strain H69AR (P＜0.05). The recombinant periostin-plasmid was transfected into H69 cells and at the same concentration of chemotherapeutic drugs (cisplatin, etoposide) the survival rate increased significantly (P＜0.05). The positive expression rate of periostin in SCLC tissues was 67.44％, and the sensitivity of the chemotherapy group was lower than that of the drug resistant group (P＜0.05). Conclusion The expression of periostin in SCLC cell H69 is significantly lower than that of the multidrug resistant strain H69AR and overexpression of periostin increases resistance of the sensitive strain H69 and hence periostin may be involved in SCLC chemoresistance.